In "COVID-19 in 2026: Why the Virus Still Threatens Vulnerable Patients," moderator Jeff Goad, PharmD, MPH is joined by ...

Antiviral therapy started within 48 hours was associated with substantially lower hospitalization (aOR, 0.19; 95% CI, ...

Chronic respiratory diseases substantially magnify pneumococcal pneumonia and invasive disease risk, with especially high CAP ...

The FDA approved tirzepatide (Mounjaro) for lowering the risk of major adverse cardiovascular events (MACE) among adults with ...

The FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer and BioNTech, Moderna, Sanofi, and Takeda within a 2-day span during August 2026, clearing 3 reformulated immunizations that target the ...

Researchers identify the resources and opportunities available for community pharmacies to incorporate climate-conscious ...

A 12-year surveillance study of invasive pneumococcal disease (IPD) has revealed a shifting serotype landscape that is ...

Through real-world strategies and examples, Duane Jones, BS Pharm, and Jennifer Griffin, PharmD, assess the pharmacist’s ...

Lifestyle counseling is described as passive and referral-oriented, highlighting an implementation gap for proactive risk ...

The combination of bictegravir and lenacapavir gives virologically suppressed adults with HIV a new option showing sustained ...

Major depressive disorder independently increases risks for preterm birth, low birth weight, hyperemesis gravidarum, cesarean ...

The findings, drawn from the Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study across 20 US hospitals, suggest reactivation is driven by inflammation rather than immune suppression and ...